• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma. Read More

Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group’s dose-limiting toxicity observation period was successfully completed. Read More

Early Symptoms, Risk Factors and Treatment Options for Esophageal Cancer

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles In a Q&A, Dr. Nataliya Uboha discussed how difficulty swallowing may signal esophageal cancer, treatment options and ongoing research to improve patient outcomes. Read More

Optune Lua Receives CE Mark in Europe for Metastatic NSCLC

by MM360 Staff | Apr 23, 2025 | Uncategorized

Source: CureToday articles Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel. Read More

How to Best Navigate a Diagnosis of Lung and Head and Neck Cancer

by MM360 Staff | Apr 23, 2025 | Uncategorized

Source: CureToday articles Dr. Douglas Reznick shares advice for patients with lung or head and neck cancer who may feel overwhelmed by their diagnosis. Read More

Joy Anderson Reflects on Her Rare Blood Disorder Diagnosis Journey

by MM360 Staff | Apr 23, 2025 | Uncategorized

Source: CureToday articles A push for answers led to a rare blood disorder diagnosis after Joy’s symptoms were initially dismissed. Read More
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability
  • Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis
  • Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
  • Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
  • Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
  • Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
  • (no title)
  • The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT